EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Chidamide Accelerates the Death of Senescence‐Like Diffuse Large B‐Cell Lymphoma Cells With TP53 Mutation Induced by Doxorubicin

Yun-Yan Yin, Yu Liu, Yi-Qi Lu, Zhi-Meng Tang, Zheng-Xin Zhu, Meng-Yuan Zhu, Hong-Yu Chen, Hui Hui iD, Jing-Yan Xu, Hui Li iD

The FASEB Journal · 2025

DOI: 10.1096/fj.202500962rr ↗

Kurz gefasst

Fachartikel in der Zeitschrift The FASEB Journal, 2025. Verfasst von Yun-Yan Yin und 9 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Carcinogenesis and Intervention, China Pharmaceutical University, Nanjing, Peopl…. Hauptthemen laut MEDLINE: Doxorubicin, Lymphoma, Large B-Cell, Diffuse, Tumor Suppressor Protein p53, Aminopyridines. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Foundation of Jiangsu Province, Fundamental Research Funds for the Central Universities, Nanjing Medical Science and Technology Development Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Diffuse large B‐cell lymphoma (DLBCL), a heterogeneous malignancy characterized by distinct genetic and clinical subtypes, remains a therapeutic challenge despite standard R‐CHOP chemotherapy. This study systematically investigated the synergistic anti‐tumor efficacy and mechanism of the histone deacetylase inhibitor chidamide (CHI) combined with doxorubicin (DOX) in DLBCL models. Through multimodal experimental approaches including CCK8 proliferation assays, senescence‐associated β‐galactosidase (SA‐β‐gal) staining analysis, comet assay for DNA damage quantification, and comprehensive western blotting for molecular mechanism elucidation, we identified a potent synergistic interaction between CHI and DOX. By constructing a xenograft tumor model, the synergistic effect of the two drugs and its mechanism in vivo were confirmed. Our research found that CHI showed cell cycle inhibition and apoptosis induction effects on DLBCL cells. When combined with DOX, both synergistically inhibited the proliferation of DLBCL cells and promoted death of DOX‐induced senescent cells. Preliminary mechanism studies revealed that CHI can reduce the level of mutant p53, inhibit cell senescence, and induce irreparable DNA damage in DOX‐induced senescent tumor cells, ultimately leading them into programmed apoptosis. Thus, the “One‐two punch” strategy increased the sensitivity of p53‐mutated DLBCL cells to CHI. In summary, our study demonstrates that CHI synergizes with DOX to suppress DLBCL and presents a promising strategy to augment the therapeutic efficacy of DOX.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DoxorubicinLymphoma, Large B-Cell, DiffuseTumor Suppressor Protein p53AminopyridinesCellular SenescenceMutationBenzamidesHumansAnimalsMiceApoptosisCell Line, TumorXenograft Model Antitumor AssaysCell ProliferationDrug SynergismDNA DamageAntibiotics, AntineoplasticMice, NudeHistone Deacetylase Inhibitors

Stichwörter der Autor:innen

DLBCLP53 mutationchidamidedoxorubicinsenescence

Substanzen

DoxorubicinN-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamideTumor Suppressor Protein p53AminopyridinesBenzamidesTP53 protein, humanAntibiotics, AntineoplasticHistone Deacetylase Inhibitors

Autor:innen und Institutionen

  • State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Carcinogenesis and Intervention, China Pharmaceutical University, Nanjing, People's Republic of China.
  • Department of Hematology, China Pharmaceutical University Nanjing Drum Tower Hospital, Nanjing, People's Republic of China.

ORCID-Profile: Hui Hui, Hui Li

Förderung

  • Natural Science Foundation of Jiangsu Province
  • Fundamental Research Funds for the Central Universities
  • Nanjing Medical Science and Technology Development Project
  • National Health Commission Center for Medical Science and Technology Development General Program for Post-Marketing Clinical Research on Innovative Drugs
  • National Natural Science Foundation of China

Zitieren

APA

Yin, Y. Y., Liu, Y., Lu, Y. Q., Tang, Z. M., Zhu, Z. X., Zhu, M. Y., Chen, H. Y., Hui, H., Xu, J. Y., & Li, H. (2025). Chidamide Accelerates the Death of Senescence‐Like Diffuse Large B‐Cell Lymphoma Cells With TP53 Mutation Induced by Doxorubicin. The FASEB Journal. https://doi.org/10.1096/fj.202500962rr

Vancouver

Yin YY, Liu Y, Lu YQ, Tang ZM, Zhu ZX, Zhu MY, et al. Chidamide Accelerates the Death of Senescence‐Like Diffuse Large B‐Cell Lymphoma Cells With TP53 Mutation Induced by Doxorubicin. The FASEB Journal. 2025. doi:10.1096/fj.202500962rr

BibTeX
@article{Yin2025,
  author = {Yin, Yun-Yan and Liu, Yu and Lu, Yi-Qi and Tang, Zhi-Meng and Zhu, Zheng-Xin and Zhu, Meng-Yuan and Chen, Hong-Yu and Hui, Hui and Xu, Jing-Yan and Li, Hui},
  title = {Chidamide Accelerates the Death of Senescence‐Like Diffuse Large B‐Cell Lymphoma Cells With TP53 Mutation Induced by Doxorubicin},
  journal = {The FASEB Journal},
  year = {2025},
  doi = {10.1096/fj.202500962rr}
}
Kostenlos starten →